Literature DB >> 27088204

[The utility of metalloproteinases (MMPs) and their inhibitors (TIMPs) in diagnostics of gynecological malignancies].

Katarzyna Mieszało1, Sławomir Ławicki2, Maciej Szmitkowski2.   

Abstract

Metalloproteinases (MMPs) are a family of proteolytic enzymes, involved in the degradation of collagen and other extracellular matrix components. They play a very important role in many physiological processes, i.e. angiogenesis, hemostasis, cyclic changes in the endometrium, wounds healing, as well as in tumor growth and spreading. Already performed studies have shown significant increase in the expression of MMP-2 and MMP-9 in the most common gynecological cancer (cervix, endometrium, ovary) compared to normal tissue and benign lesions. In addition, the MMP-9 concentration correlated with the clinical stage and the presence of distant metastases. Moreover the level of MMP-2 was significantly associated with the degree of malignancy. MMP-7 may be helpful in the diagnosis of ovarian cancer and useful in estimating of lymph node metastasis presence in endometrial cancer. In the detection of cervical cancer it may be useful to evaluate the expression of MMP-11 and MMP-12 (absent in normal cells) and their increase according to the degree of tissue damage. The usefulness of metalloproteinases in the diagnosis of gynecological cancer still requires confirmation test. However, it appears that they will be valuable factors in diagnostic complement, especially in combination with conventional markers, i.e. CA 125, SCCAg or HE-4.
© 2016 MEDPRESS.

Entities:  

Keywords:  cervical cancer; endometrial cancer; gynecological malignancies; matrix metalloproteinases (MMPs); ovarian cancer

Mesh:

Substances:

Year:  2016        PMID: 27088204

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  6 in total

1.  Knockdown of ENTPD5 inhibits tumor metastasis and growth via regulating the GRP78/p-eIF-2α/CHOP pathway in serous ovarian cancer.

Authors:  Xueping Chen; Zhiqiang Zha; Yu Wang; Yun Chen; Menglan Pang; Liping Huang; Yao Chen
Journal:  J Ovarian Res       Date:  2022-06-07       Impact factor: 5.506

Review 2.  Adaptive mechanisms of resistance to anti-neoplastic agents.

Authors:  Bibiana I Ferreira; Maria K Lie; Agnete S T Engelsen; Susana Machado; Wolfgang Link; James B Lorens
Journal:  Medchemcomm       Date:  2016-10-21       Impact factor: 3.597

3.  Therapy of psoriasis with narrowband ultraviolet-B light influences plasma concentrations of MMP-2 and TIMP-2 in patients.

Authors:  Edyta Katarzyna Głażewska; Marek Niczyporuk; Sławomir Ławicki; Maciej Szmitkowski; Monika Zajkowska; Grażyna Ewa Będkowska; Andrzej Przylipiak
Journal:  Ther Clin Risk Manag       Date:  2016-10-21       Impact factor: 2.423

4.  Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9.

Authors:  Huidi Liu; Zheng Zeng; Siwen Wang; Ting Li; Emilio Mastriani; Qing-Hai Li; Hong-Xia Bao; Yu-Jie Zhou; Xiaoyu Wang; Yongfang Liu; Wei Liu; Sijing Hu; Shan Gao; Miao Yu; Yingying Qi; Zhihang Shen; Hongyue Wang; Tingting Gao; Lingqin Dong; Randal N Johnston; Shu-Lin Liu
Journal:  Cancer Biol Ther       Date:  2017-11-27       Impact factor: 4.742

5.  Expression and clinical significance of serum MMP-7 and PTEN levels in patients with acute myeloid leukemia.

Authors:  Jiang Wu; Yu Song
Journal:  Oncol Lett       Date:  2018-01-15       Impact factor: 2.967

6.  Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.

Authors:  Monika Zajkowska; Monika Zbucka-Krętowska; Iwona Sidorkiewicz; Emilia Lubowicka; Grażyna Ewa Będkowska; Ewa Gacuta; Maciej Szmitkowski; Sławomir Ławicki
Journal:  Cancer Control       Date:  2018 Jan-Dec       Impact factor: 3.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.